News

Video

New PRO instrument helps measure patient experience with therapies such as anti-VEGF agents, lasers to treat their eye disease

Diana Do, MD, professor of ophthalmology at Stanford's Byers Eye Institute, presents research on a newly developed, novel patient-reported outcome instrument (PRO) for patients who have proliferative diabetic retinopathy and who are undergoing treatment with either intravitreal anti-VEGF therapy, or panretinal photocoagulation.

This video transcript has been lightly edited for clarity.

Hi, I'm Dr. Diana Do, professor of ophthalmology at the Byers Eye Institute at Stanford University.

I had the pleasure of presenting research that our team conducted looking at developing a novel patient reported outcome instrument for patients who have proliferative diabetic retinopathy and who are undergoing treatment with either intravitreal anti-VEGF therapy, or panretinal photocoagulation.

We decided to embark on this project because we realize there is no pre-existing patient-reported outcome (PRO) instrument that truly captures the patient experience of patients who are undergoing these therapies for their vision threatening eye disease.

We did an extensive literature review, then a round of interviews with both retina specialists and over 80 patients to understand their treatment experience.

From that, we developed a new novel PRO instrument which we call the diabetic retinopathy scale, and we hope to validate this instrument in more patients to truly capture how they feel they experience with therapies such as anti-VEGF agents, or with laser to treat their eye disease.

I look forward to giving you more updates in the near future.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) Inside NYEE’s new refractive solutions center with Kira Manusis, MD
(Image credit: Ophthalmology Times) Dilsher Dhoot, MD, on the evolution of geographic atrophy therapy: where are we now?
(Image credit: Ophthalmology Times Europe) Anat Loewenstein, MD, shares insights on the real-world results of remote retinal imaging
(Image credit: Ophthalmology Times) Two-wavelength autofluorescence for macular xanthophyll carotenoids with Christine Curcio, PhD
(Image credit: Ophthalmology Times) FLIO and the brain: Making the invisible visible with Robert Sergott, MD
(Image credit: Ophthalmology Times) Structure-function correlates using high-res OCT images with Karl Csaky, MD, PhD
(Image credit: Ophthalmology Times) SriniVas Sadda, MD, on high-res OCT of atrophic and precursor lesions in AMD
(Image credit: Ophthalmology Times) Christine Curcio, PhD, shares histology update supporting review software and revised nomenclature for <3 μm OCT
1 expert is featured in this series.
© 2025 MJH Life Sciences

All rights reserved.